Nomura Holdings
BBIO icon

Nomura Holdings’s BridgeBio Pharma BBIO Stock Holding History

Nomura Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4M Buy
327,475
+8,912
+3% +$624K 0.03% 317
2026
Q1 		$23.7M Buy
318,563
+8,633
+3% +$626K 0.06% 208
2025
Q4 		$23.7M Sell
309,930
-122,152
-28% -$8.02M 0.03% 277
2025
Q3 		$22.4M Buy
432,082
+160,972
+59% +$7.85M 0.03% 294
2025
Q2 		$11.7M Buy
271,110
+30,296
+13% +$1.1M 0.02% 362
2025
Q1 		$8.32M Buy
240,814
+26,686
+12% +$900K 0.02% 532
2024
Q4 		$5.88M Sell
214,128
-11,109
-5% -$287K 0.01% 706
2024
Q3 		$5.73M Sell
225,237
-2,997
-1% -$78.7K 0.01% 610
2024
Q2 		$5.78M Sell
228,234
-153,411
-40% -$4.19M 0.01% 628
2024
Q1 		$11.8M Buy
381,645
+123,650
+48% +$4.21M 0.03% 390
2023
Q4 		$10.4M Buy
257,995
+22,986
+10% +$690K 0.03% 442
2023
Q3 		$6.2M Sell
235,009
-90,744
-28% -$2.58M 0.02% 465
2023
Q2 		$5.6M Buy
325,753
+80,658
+33% +$1.21M 0.02% 461
2023
Q1 		$4.06M Buy
245,095
+129,558
+112% +$1.51M 0.01% 620
2022
Q4 		$878K Sell
115,537
-47,343
-29% -$453K ﹤0.01% 869
2022
Q3 		$1.62M Buy
162,880
+15,895
+11% +$165K 0.01% 852
2022
Q2 		$1.46M Sell
146,985
-8,826
-6% -$73.8K 0.01% 872
2022
Q1 		$1.69M Sell
155,811
-71,046
-31% -$729K 0.01% 932
2021
Q4 		$3.79M Buy
226,857
+1,878
+0.8% +$79.5K 0.01% 800
2021
Q3 		$10.7M Buy
224,979
+1,516
+0.7% +$81.3K 0.03% 373
2021
Q2 		$13.6M Buy
223,463
+249
+0.1% +$14.2K 0.03% 296
2021
Q1 		$13.7M Buy
223,214
+218,884
+5,055% +$14.3M 0.03% 270
2020
Q4 		$308K Sell
4,330
-9,368
-68% -$452K ﹤0.01% 1324
2020
Q3 		$514K Buy
+13,698
New +$431K ﹤0.01% 998

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nomura Holdings's BBIO Position: Q2 2026 in Review

Nomura Holdings increased its BridgeBio Pharma (BBIO) stake by 2.8% in Q2 2026, buying an estimated $624K and bringing the position to 327,475 shares worth $24.4M. The position accounts for 0.03% of the portfolio, ranked #317.

Nomura Holdings first reported a position in BBIO in Q3 2020 and has held it in 24 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Nomura Holdings held 327,475 shares of BridgeBio Pharma worth $24.4M as of Q2 2026.
  • Nomura Holdings bought 8,912 BridgeBio Pharma shares in Q2 2026, an estimated $624K.
  • BridgeBio Pharma made up 0.03% of Nomura Holdings's portfolio in Q2 2026, its #317 holding.
  • Nomura Holdings first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 24 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.